Pharmacokinetically guided dose adjustment of 5-fluorouracil: A rational approach to improving therapeutic outcomes

Journal of the National Cancer Institute

Volumn 101, Issue 22, 2009, Pages 1543-1552

  Saif, M Wasif ^a   Choma, Adrienne ^b   Salamone, Salvatore J ^b   Chu, Edward ^a  

^a YALE CANCER CENTER   (United States)

^b SALADAX BIOMEDICAL INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; THYMIDYLATE SYNTHASE;

AREA UNDER THE CURVE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CHRONIC DISEASE; CIRCADIAN RHYTHM; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY; DISEASE FREE INTERVAL; DISEASE FREE SURVIVAL; DNA SYNTHESIS; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; HAND FOOT SYNDROME; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOASSAY; METASTASIS; MONOTHERAPY; MORTALITY; MUCOSA INFLAMMATION; NEUROTOXICITY; PATIENT SAFETY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; STOMATITIS; SYSTEMIC THERAPY; UNITED STATES;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CIRCADIAN RHYTHM; CLINICAL TRIALS AS TOPIC; DIHYDROURACIL DEHYDROGENASE (NADP); DRUG ADMINISTRATION SCHEDULE; FLUOROURACIL; HUMANS; THYMIDYLATE SYNTHASE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 72949086481     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djp328     Document Type: Review

References (71)

1. Hillcoat BL, McCulloch PB, Figueredo AT, Ehsan MH, Rosenfeld JM. Clinical response and plasma levels of 5-fl uorouracil in patients with colonic cancer treated by drug infusion. Br J Cancer. 1978 ; 38 (6): 719-724.
2. Kirkwood JM, Ensminger W, Rosowsky A, Papathanasopoulos N, Frei E III. Comparison of pharmacokinetics of 5-fl uorouracil and 5-fl uorouracil concurrent thymidine infusions in a phase I trial. Cancer Res. 1980 ; 40 (1): 107-113.
3. Au JL, Rustum YM, Ledesma EJ, Mittelman A, Creaven PJ. Clinical pharmacological studies of concurrent infusion of 5-fl uorouracil and thymidine in treatment of colorectal carcinomas. Cancer Res. 1982 ; 42 (7): 2930-2937.
4. van Groeningen CJ, Pinedo HM, Heddes J, et al. Pharmacokinetics of 5-fl uorouracil assessed with a sensitive mass spectrometric method in patients on a dose escalation schedule. Cancer Res. 1988 ; 48 (23): 6956-6961.
5. Yoshida T, Araki E, Iigo M, et al. Clinical signifi cance of monitoring serum levels of 5-fl uorouracil by continuous infusion in patients with advanced colonic cancer. Cancer Chemother Pharmacol. 1990 ; 26 (5): 352-354.
6. Trump DL, Egorin MJ, Forrest A, et al. Pharmacokinetic and pharmaco-dynamic analysis of fl uorouracil during 72-hour continuous infusion with and without dipyridamole. J Clin Oncol. 1991 ; 9 (11): 2027-2035.
7. Smith CG, Grady JE, Kupiecki FP. Blood and urine levels of antitumor agents determined with cell culture methods. Cancer Res. 1965 ; 25: 241-245.
8. Clarkson B, O ' Connor A, Winston L, Hutchinson D. The physiologic disposition of 5-fl uorouracil and 5-fl uoro-2 ′-deoxyuridine in man. Clin Pharmacol Ther. 1964 ; 5: 581-610.
9. Cohen JL, Brennan PB. GLC assay for 5-fl uorouracil in biological fl uids. J Pharm Sci. 1973 ; 4 (4): 572-575.
10. Hillcoat BL, Kawai M, McCulloch PB, Rosenfeld J, Williams CKO. A sensitive assay of 5-fl uorouracil in plasma by gas chromatography-mass spectrometry. Br J Clin Pharmacol. 1976 ; 38 (1): 719-724.
11. Christophidis N, Mihaly G, Vajda F, Louis W. Comparison of liquid-and gas-liquid chromatographic assays of 5-fl uorouracil in plasma. Clin Chem. 1979 ; 25 (1): 83-86.
12. Ciccolini J, Mercier C, Blachon MF, et al. A simple and rapid high-performance liquid chromatographic (HPLC) method for 5-fl uorouracil (5-FU) assay in plasma and possible detection of patients with impaired dihydropyrimidine dehydrogenase (DPD) activity. J Clin Pharm Ther. 2004 ; 29 (4): 307-315.
13. Kosovec JE, Egorin MJ, Gjurich S, Beumer JH. Quantitation of 5-fluorouracil (5-FU) in human plasma by liquid chromatography/ electrospray ionization tandem mass spectrometry. Rapid Commun Mass Spectrom. 2008 ; 22 (2): 224-230.
14. Beumer JH, Boisdron-Celle M, Clarke W, et al. Multicenter evaluation of a novel nanoparticle immunoassay for 5-fl uorouracil on the Olympus AU400 analyzer. [published online whead of print september 4, 2009]. Ther Drug Monit.
15. de Gramont A, Bosset JF, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fl uorouracil bolus with bimonthly high-dose leucovorin and fl uorouracil bolus plus continuous infusion for advanced colorectal cancer: a French Intergroup Study. J Clin Oncol. 1997; 15 (2): 808-815.
16. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fl uorouracil with or without oxaliplatin as fi rst-line treatment in advanced colorectal cancer. J Clin Oncol. 2000 ; 18 (16): 2938-2947.
17. Gamelin E, Boisdron-Celle M. Dose monitoring of 5-fl uorouracil in patients with colorectal or head and neck cancer - status of the art. Crit Rev Oncol Hematol. 1999 ; 30 (1): 71-79.
18. Gamelin EC, Danquechin-Dorval EM, Dumesnil YF, et al. Relationship between 5-fl uorouracil dose-intensity and therapeutic response in patients with advanced colorectal cancer receiving 5-FU containing infusional therapy. Cancer. 1996 ; 77 (3): 441-451.
19. Gamelin E, Boisdron-Celle M, Delva R, et al. Long-term weekly treatment of colorectal metastatic cancer with fl uorouracil and leucovorin: results of a multicentric prospective trial of fl uorouracil dosage optimization by pharmacokinetic monitoring in 152 patients. J Clin Oncol. 1998 ; 16 (4): 1470-1478.
20. Gamelin E, Jacob J, Danquechin-Dorval E, et al. Multicentric randomized trial comparing in weekly treatment of advanced colorectal cancer (CRC) intensifi ed 5-fl uorouracil and folinic acid (FA) with pharmacokinetic monitoring to a constant dose calculated with body surface area [abstract 1039]. Proc Am Soc Clin Oncol. 1998 ; 16.
21. Gamelin E. 5-Fluorouracil dose management. Clin Colorectal Cancer. 2007 ; 7 (6): 411-413.
22. Gamelin E, Jacob J, Merrouche Y, et al. Individual 5-fl uorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial in patients with metastatic colorectal cancer. J Clin Oncol. 2008 ; 26 (13): 2099-2105.
23. Ychou M, Duffour J, Pinguet F, et al. Individual 5FU-dose adaptation schedule using bimonthly pharmacokinetically modulated LV5FU2 regimen: a feasibility study in patients with advanced colorectal cancer. Anticancer Res. 1999 ; 19 (3B): 2229-2235.
24. Ychou M, Duffour J, Kramar A, et al. Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensifi ed LV5FU2 regimen. Cancer Chemother Pharmacol. 2003 ; 52 (4): 282-290.
25. Capitain O, Boisdron-Celle M, Poirier A-L, et al. The infl uence of fl uo-rouracil outcome parameters on tolerance and effi cacy in patients with advanced colorectal cancer. Pharmacogenomics J. 2008 ; 8 (4): 256-267.
26. Gamelin E, Boisdron-Celle M, Guerin-Meyer V, et al. Comparison of two patient cohorts treated in parallel for advanced colorectal cancer with a simplifi ed FOLFOX 4 regimen with or without 5-FU therapeutic dose management [abstract 356]. Proc Am Soc Clin Oncol-GI. 2009.
27. Capitain O, Asevoaia A, Boisdron-Celle M, et al. Infl uence of pharmaco-genetic and epigenetic factors on 5-fl uorouracil and irinotecan (FOLFIRI) effi cacy and tolerance in patients treated for advanced colorectal cancer [abstract 429]. Gastrointestinal Cancers Symposium. 2008.
28. Di Paolo A, Lencioni M, Amatori F, et al. 5-Fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer. Clin Cancer Res. 2008 ; 14 (9): 2749-2755.
29. Fety R, Rolland F, Barberi-Heyob M, et al. Clinical impact of pharmacokinetically-guided dose adaptation of 5-fl uorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas. Clin Cancer Res. 1998 ; 4 (9): 2039-2045.
30. Baker SD, Verweij J, Rowinsky EK, et al. Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. J Natl Cancer Inst. 2002 ; 94 (24): 1883-1888.
31. Undevia SD, Gomez-Abuin G, Ratain MJ. Pharmacokinetic variability of anticancer agents. Nat Rev Cancer. 2005 ; 5 (6): 447-458.
32. Krynetski EY, Evans WE. Pharmacogenetics of cancer therapy: getting personal. Am J Hum Genet. 1998 ; 63 (1): 11-16.
33. Hon YY, Evans WE. Making TDM work to optimize cancer chemotherapy: a multidisciplinary team approach. Clin Chem. 1998 ; 44 (2): 388-400.
34. McDonald GB, Slattery JT, Bouvier ME, et al. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood. 2003 ; 101 (5): 2043-2048.
35. de Jonge ME, Huitema ADR, Schellens JHM, et al. Individualised cancer chemotherapy: strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation: a review. Clin Pharmacokinet. 2005 ; 44 (2): 147-173.
36. Partridge AH, Avorn J, Wang PS, et al. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst. 2002 ; 94 (9): 652-661.
37. Gamelin E, Boisdron-Celle M, Guérin-Meyer V, et al. Correlation between uracil and dihydrouracil plasma ratio, and 5-fl uorouracil pharma-cokinetic parameters and tolerance in patients with advanced colorectal cancer. A potential interest for predicting 5-FU toxicity and for determining optimal 5-FU dosage. J Clin Oncol. 1999 ; 17 (4): 1105-1110.
38. Milano G, Etienne MC, Cassuto-Viguier E, et al. Infl uence of sex and age on fl uorouracil clearance. J Clin Oncol. 1992 ; 10 (7): 1171-1175.
39. Chabner BA. Clinical pharmacokinetics and drug monitoring in cancer. In: Chabner BA, Longo DL, eds. Chemotherapy and Biotherapy, Principles and Practice. 2nd ed. Philadelphia, PA: Lippincott-Raven ; 1996. chap 5.
40. Goldberg RM, Rothenberg ML, Van Cutsem E, et al. The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist. 2007 ; 12 (1): 38-50.
41. Kelly H, Goldberg RM. Systemic therapy for metastatic colorectal cancer: current options, current evidence. J Clin Oncol. 2005 ; 23 (20): 4553-4560. (Pubitemid 46196586)
42. Santini J, Milano G, Thyss A, et al. 5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer. Br J Cancer. 1989 ; 59 (2): 287-290.
43. Milano G, Etienne MC, Renee N, et al. Relationship between fl uorouracil systemic exposure and tumor response and patient survival. J Clin Oncol. 1994 ; 12 (6): 1291-1295.
44. Vokes EE, Mick R, Kies MS, et al. Pharmacodynamics of fl uorouracil-based induction chemotherapy in advanced head and neck cancer. J Clin Oncol. 1996 ; 14 (5): 1663-1671.
45. Beumer JH, Egorin MJ, Milano G, et al. A rapid nanoparticle immunoassay to quantitate 5-fl uorouracil (5-FU) in plasma [abstract 421]. Gastrointestinal Cancers Symposium. 2008.
46. Ploylearmsaeng SA, Fuhr U, Jetter A. How may anticancer chemotherapy with fl uorouracil be individualised? Clin Pharmacokinet. 2006 ; 45 (6): 567-592.
47. Heggie GD, Sommadossi JP, Cross DS, et al. Clinical pharmacokinetics of 5-fl uorouracil and its metabolites in plasma, urine, and bile. Cancer Res. 1987 ; 47 (8): 2203-2206.
48. Harris BE, Song R, Soong SJ, Diasio RB. Relationship between dihydro-pyrimidine dehydrogenase activity and plasma 5-fl uorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fl uorouracil by protracted continuous infusion. Cancer Res. 1990 ; 50 (1): 197-201.
49. DiPaolo A, Danesi R, Falcone A, et al. Relationship between 5-fl uorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients. Ann Oncol. 2001 ; 12 (9): 1301-1306.
50. van Kuilenburg AB, Haasjes J, Richel DJ, et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) defi ciency in patients with severe 5-fl uorouracil-associated toxicity: identifi cation of new mutations in the DPD gene. Clin Cancer Res. 2000 ; 6 (12): 4705-4712.
51. Ezzeldin H, Diasio R. Dihydropyrimidine dehydrogenase defi ciency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fl uorouracil administration. Clin Colorectal Cancer. 2004 ; 4 (3): 181-189.
52. Etienne MC, Lagrange JL, Dassonville O, et al. Population study of dihy-dropyrimidine dehydrogenase in cancer patients. J Clin Oncol. 1994 ; 12 (11): 2248-2253.
53. Diasio RB. Clinical implications of dihydropyrimidine dehydrogenase on 5-FU pharmacology. Oncology. 2001 ; 15 (1 suppl 2): 21-26; discussion 27.
54. Milano G, Etienne MC. Individualizing therapy with 5-fl uorouracil related to dihydropyrimidine dehydrogenase: theory and limits. Ther Drug Monit. 1996 ; 18 (4): 335-340.
55. Boisdron-Celle M, Remaud G, Traore S, et al. 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase defi ciency. Cancer Lett. 2007; 249 (2): 271-282.
56. Lu Z, Zhang R, Carpenter JT, Diasio RB. Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer: implication for 5-fl uorouracil-based chemotherapy. Clin Cancer Res. 1998 ; 4 (2): 325-329.
57. Johnson MR, Diasio RB. Importance of dihydropyrimidine dehydroge-nase (DPD) defi ciency in patients exhibiting toxicity following treatment with 5-fl uorouracil. Adv Enzyme Regul. 2001 ; 41: 151-157.
58. Bocci G, Barbara C, Vannozzi F, et al. A pharmacokinetic-based test to prevent severe 5-fl uorouracil toxicity. Clin Pharmacol Ther. 2006 ; 80 (4): 384-395.
59. Leichman CG, Lenz HJ, Leichman L, et al. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fl uorouracil and weekly leucovorin. J Clin Oncol. 1997 ; 15 (10): 3223-3229.
60. Aschele C, Debernardis D, Casazza S, et al. Immunohistochemical quan-titation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fl uorouracil-based chemotherapy. J Clin Oncol. 1999 ; 17 (6): 1760-1770.
61. Cascinu S, Aschele C, Barni S, et al. Thymidylate synthase protein expression in advanced colon cancer: correlation with the site of metastasis and the clinical response to leucovorin-modulated bolus 5-fl uorouracil. Clin Cancer Res. 1999 ; 5 (8): 1996-1999.
62. Horie N, Aiba H, Ogura K, et al. Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5 ′ terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct. 1995 ; 20 (3): 191-197.
63. Pullarkat ST, Stoehlmacher J, Ghaderi V, et al. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J. 2001 ; 1 (1): 65-70.
64. Lecomte T, Ferraz JM, Zinzindohoue F, et al. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fl uorouracil-based chemotherapy. Clin Cancer Res. 2004 ; 10 (17): 5880-5888.
65. Schwab M, Zanger UM, Marx C, et al. Role of genetic and nongenetic factors for fl uorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol. 2008; 26 (13): 2131-2138.
66. Milano G, Chamorey AL. Clinical pharmacokinetics of 5-fl uorouracil with consideration of chronopharmacokinetics. Chronobiol Int. 2002 ; 19 (1): 177-189.
67. Levi FA, Zidani R, Vannetzel JM, et al. Chronomodulated versus fi xed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fl uo-rouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. J Natl Cancer Inst. 1994 ; 86 (21): 1608-1617.
68. Fleming GF, Schilsky RL, Mick R, et al. Circadian variation of 5-fl uorouracil plasma levels during continuous infusion 5-FU and leucovorin in patients with hepatic or renal dysfunction. Ann Oncol. 1994 ; 5 (suppl 5): 236.
69. Takimoto CH, Yee LK, Venzon DJ, et al. High inter-and intrapatient variation in 5-fl uorouracil plasma concentrations during a prolonged drug infusion. Clin Cancer Res. 1999 ; 5 (6): 1347-1352.
70. Meropol NJ, Schulman KA. Cost of cancer care: issues and implications. J Clin Oncol. 2007 ; 25 (2): 180-186.
71. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as fi rst-line therapy in metastatic colorec-tal cancer. J Clin Oncol. 2008 ; 26 (12): 2013-2019